Region Skane

skane.se

Total trials

367

Active

124

Phase 3

8

Total enrollment

494,639

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 18 of 18 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Ropivacain 5 mg/ml + Clonidine2
Shingrix2
Adenosine1
Penicillin G_1200mg1
cloxacillin1
Collagenase Clostridium Histolyticum1
vaccination with 2 doses of Shingrix vaccine1
Afatinib/Dacomitinib1
Osimertinib1
L-menthol3
Aliskiren1
Enalapril1
Semaglutide1
Dapagliflozin1
Psilocybin1
STEM-PD1
Chemotherapy1
TNF-inhibition1

Next readouts

  • 2021-12-15
  • 2024-09-01
  • 2025-03-30
  • 2025-12-31
  • 2026-10-01
  • 2026-12
  • 2026-12-31
  • 2027-01
  • 2027-02
  • 2027-03-01

Top conditions

  • Breast Cancer9
  • Osteoarthritis7
  • Suicide, Attempted6
  • Stroke6
  • Depression6
  • Cancer5
  • Septic Shock5
  • Carpal Tunnel Syndrome5

Frequently asked questions about Region Skane

How many clinical trials does Region Skane have on ClinicalTrials.gov?
Region Skane is listed as the lead sponsor on 367 clinical trials in ClinicalTrials.gov, 124 of which are currently active (recruiting, enrolling, or ongoing).
How many of Region Skane's trials are in Phase 3?
8 of Region Skane's trials are in Phase 3, spread across 18 active drug programs.
What therapeutic areas does Region Skane focus on?
Region Skane's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Osteoarthritis, Suicide, Attempted, Stroke, Depression.
When are Region Skane's next clinical trial readouts?
Region Skane has 10 upcoming primary-completion readouts tracked here; the soonest is “Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology”, expected around 2021-12-15.